Analysts predict that Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) will report earnings per share of ($0.54) for the current quarter, Zacks reports. Three analysts have made estimates for Crinetics Pharmaceuticals’ earnings. The highest EPS estimate is ($0.51) and the lowest is ($0.55). Crinetics Pharmaceuticals posted earnings of ($0.38) per share in the same quarter last year, which would suggest a negative year over year growth rate of 42.1%. The business is expected to issue its next quarterly earnings results on Tuesday, November 12th.

On average, analysts expect that Crinetics Pharmaceuticals will report full year earnings of ($2.05) per share for the current fiscal year, with EPS estimates ranging from ($2.29) to ($1.90). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.82) per share, with EPS estimates ranging from ($3.33) to ($2.35). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its earnings results on Tuesday, August 13th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.05). Crinetics Pharmaceuticals had a negative net margin of 1,303.31% and a negative return on equity of 24.12%.

Several analysts have commented on the stock. ValuEngine upgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Zacks Investment Research upgraded shares of Crinetics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $34.33.

NASDAQ CRNX traded up $0.09 during trading on Friday, reaching $19.23. 37,800 shares of the company’s stock traded hands, compared to its average volume of 63,762. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.07 and a quick ratio of 19.07. Crinetics Pharmaceuticals has a 12-month low of $14.33 and a 12-month high of $36.95. The company’s 50 day simple moving average is $16.78 and its two-hundred day simple moving average is $21.01. The firm has a market cap of $454.48 million, a price-to-earnings ratio of -8.62 and a beta of 0.88.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Orbimed Advisors LLC lifted its stake in Crinetics Pharmaceuticals by 6.5% during the 2nd quarter. Orbimed Advisors LLC now owns 2,039,282 shares of the company’s stock valued at $50,982,000 after acquiring an additional 125,000 shares during the period. BlackRock Inc. increased its holdings in shares of Crinetics Pharmaceuticals by 19.9% during the 2nd quarter. BlackRock Inc. now owns 932,424 shares of the company’s stock valued at $23,312,000 after purchasing an additional 154,450 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Crinetics Pharmaceuticals by 11.6% during the 2nd quarter. Vanguard Group Inc. now owns 504,539 shares of the company’s stock valued at $12,614,000 after purchasing an additional 52,327 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Crinetics Pharmaceuticals by 2.3% during the 2nd quarter. Janus Henderson Group PLC now owns 499,542 shares of the company’s stock valued at $12,489,000 after purchasing an additional 11,175 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Crinetics Pharmaceuticals by 0.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 487,916 shares of the company’s stock valued at $12,198,000 after purchasing an additional 1,786 shares in the last quarter. Institutional investors and hedge funds own 78.20% of the company’s stock.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Featured Story: Penny Stocks

Get a free copy of the Zacks research report on Crinetics Pharmaceuticals (CRNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.